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Cancer stem cells (CSCs) play a pivotal role in tumor development,
progression and recurrence after treatment. CSCs are deﬁned as tumor
cells that have an unlimited potential of cell division and an ability to re-
populate the whole tumor [1]. For radiotherapy as well as for other po-
tentially curative anti-cancer treatments, this deﬁnition implies that all
CSCs need to be inactivated in order to permanently eradicate a tumor.
The long established gold standard assay to determine CSCs is a func-
tional assay, i.e. the tumor cell transplantation assay measuring the
cell number needed to be injected to cause tumor takes in 50% (TD50)
of the experimental animals. Technological advances allow us to identi-
fy and sort tumor cells for CSC-rich and CSC-low subpopulations, e.g. by
cell surface marker expression. Such markers can in many cases also be
identiﬁed by using staining techniques in tumor sections or by gene ex-
pression arrays, ensuring clinical applicability of such parameters for
biomarker assays. However, limitations occur from the fact that thresh-
old values for staining intensity cannot be determined by direct valida-
tion of the stemness of the stained tumors cells and from the general
fact applying to all CSC marker assays, that the marker expression is
not speciﬁc to CSCs but just determines cells that have a higher likeli-
hood to express CSC features. Thus, stemness of cells has still to be val-
idated by the functional assays mentioned above [2,3].
Because of their importance for tumor curability, CSCs can beutilized
for strategies to optimize anti-cancer treatments by their evaluation as
markers for patient stratiﬁcation to speciﬁc intensiﬁed or de-escalated
treatment strategies and/or by developing treatment approaches that
speciﬁcally target tumor cells expressing putative CSC markers.2. Radioresistance determined by cancer stem cells
If other confounding factors are constant, the radiation dose to erad-
icate a tumor inversely correlates with the logarithm of the number of
CSCs, i.e. at the same radiotherapy dose tumors with a lower number
of CSCs show higher local control rates compared with tumors with
higher numbers of CSCs. In experimental and clinical data, this leads
to a tumor volume dependence of the curability of tumors, because
the absolute number of CSCs is expected to increase with tumor volume
[2–6]. However, also densities of CSCs can differ between tumors, again
impacting local tumor control after radiotherapy [6,7]. The dependence
of local tumor control from the number of CSCs contained in a tumor is
underlined by the log-linear correlation between the TD50 and the radi-
ation dose necessary to permanently cure 50% of the tumors (tumor
control dose 50%, TCD50) [3,8]. This correlation indicates that, even
though CSCs seem to express a constant plasticity, TCD50 is a valuable
correlate of the number of CSCs in a given tumor. Nevertheless, some
of the described tumormodelswith equal TD50 showsigniﬁcant discor-
dance in TCD50 values, suggesting that in addition to the total number
of CSCs in a given tumor, the inherent radiosensitivity of CSCs as well
as other radiobiological parameters may impact local tumor control
after irradiation [2,8]. Such differences of intrinsic radiosensitivity be-
tween colony-forming cells in vitro (clonogenic cells) of tumors with
the same histology have been shown by the variation of the surviving
fraction at 2 Gy (SF2) in colony-forming in vitro assays, which in some
studies correlate with clinically observed differences in radiosensitivity
between tumor entities or within the same histology [3,9,10]. The same
correlation between radiosensitivity of clonogenic cells in vitro and
tumor radiocurability in vivo exists for tumors of different histologies
[11–14], supporting a correlation between clonogenicity in vitro and
stemness in vivo and the importance of intrinsic radiosensitivity of
CSCs for radiocurability of tumors. Of note, such preclinical data on
established tumormodels are of high importance for our today's under-
standing of the biology of CSC, however, speciﬁc questions especially
concerning detailed gene expressions or tumor to normal tissue interac-
tions may in many cases require the use of primary xenografts. It is notthe scope of this review to discuss the use of different experimental
models in detail.
Taking into account that tumors can potentially arise from a single
CSC, a failure of radiation treatment might be attributed to the incom-
plete eradication of the entire CSC population [3,15]. The cure rate of ir-
radiation results from its ability to induce DNA damage in tumor tissue
through production of the water-derived reactive oxygen species or by
direct ionization of the DNA molecules [16]. At the cellular level, DNA
damage has long and short term consequences. An acute effect is related
to the disturbance of DNAmetabolism such as DNA replication and RNA
transcription. Based on the status of DNA repair and the nature of the
DNA lesions, the outcomeofDNA injury canbe temporary or permanent
cell arrest, immediate or delayed cell death or mutagenesis of the sur-
viving cells, which in turn might lead to genomic instability and subse-
quently results in tumor development in a long term perspective [17].
The biological consequences of irradiation leading to cell death are
highly inﬂuenced by the activation of the DNA damage response
(DDR) mechanisms. Among the various types of DNA damages pro-
duced by ionizing irradiation, i.e. single strand breaks (SSBs), double
strand breaks (DSBs), damaged nucleotide bases or abasic sites, DSBs
represent the principal lesions that might lead to cell death if not ade-
quately repaired [16]. Both normal and tumor cells can repair DSBs
by either error-free homology-directed recombination (HR) or error-
prone non-homologous end joining (NHEJ) mechanisms which are act-
ing in an overlapping and complementary manner [18]. In addition to
the activation of DNA repair process, DNA damage induces checkpoint
kinase signaling pathways such as ataxia telangiectasia mutated
(ATM)-checkpoint kinase 2 (Chk2) and ATM-Rad3-related (ATR)-
checkpoint kinase (Chk1) which delay cell cycle progression in order
to allow DNA repair [18]. When DNA damage is beyond the cell repair
capacity, proteins of DDR signaling mediate cellular death or loss of
reproductive capacity through activation of different pathways such as
apoptosis, senescence or mitotic catastrophe [19]. Therefore, the efﬁca-
cy of the DNA repair machinery activated by the DNA damage signaling
network is critical and determines cell death or repair. A high DNA re-
pair capacity has been described for CSC populations in different
tumor entities including glioblastoma, prostate, lung and breast cancers
and mainly attributed to the activation of the ATR-Chk1 and ATM-Chk2
signaling pathways [20–30], as summarized in Table 1.
Radiation-induced cell death occurs not only by a direct energy
transfer to the DNA but, in case of conventional photon radiotherapy,
mainly as a result of generation of the free radicals, including the chem-
ically reactive products of oxygen metabolism called reactive oxygen
species (ROS) [31]. Under physiological conditions, these metabolites
are involved in the signaling events regulating different cellular pro-
cesses such as differentiation, proliferation, autophagy and survival
[32]. However, if ROS production is beyond the capacity of the cellular
antioxidant system, it may lead to the irreversible oxidative stress
and cell death [33]. The physiological ROS level is maintained by
the scavenging molecules such as glutathione, dismutase, peroxidase,
thioredoxin, catalase, and superoxide [33]. In addition, adverse effect
of ROS can be also minimized by an adequate DDR response [34]. A
highly efﬁcient ROS scavenging system or generally lower ROS levels
in CSC may contribute to the high resistance of CSC populations to
genotoxic stress described for different tumor entities [35–38] (Table 1).
Besides the above-described intrinsic mechanisms underlying CSC
radioresistance, the CSC fate under physiological conditions and during
treatment is tightly regulated by a broad range of extrinsic microenvi-
ronmental stimuli [39,40]. Within a tumor, CSCs can reside in speciﬁc
niches occupying different locations including hypoxic, perivascular
and invasive tumor areas that can dynamically change during tumor de-
velopment and treatment [41,42]. A CSC niche is deﬁned by various sol-
uble factors, extracellular matrix (ECM) elements and direct cell–cell
interactions via cell surface molecules. Depending on oxygen tension,
a niche occupied by CSCs may deﬁne differentiation, self-renewal and
treatment resistance of the CSCs. The CSCs residing in the hypoxic
Table 1
The mechanisms of CSC radioresistance.
Mechanism Signaling pathway CSC population Inhibition of CSC resistance CSC origin Reference
Activation of DNA repair ATR-Chk1
PARP
CSCs enriched under selective culture condition Combined inhibition of ATM (KU55933) and PARP
(olaparib), ATR (VE821) and Chk1 (SCH900776 and
CHIR-124)
Primary patient derived
glioblastoma cell lines
[19]
ATM-Chk1 CSCs enriched under selective culture condition Inhibition of ATM with KU-55,933 Primary patient derived
glioblastoma cell lines
[20]
Myc-dependent activation of Chk1 and Chk2 PKH26+ nasopharyngeal carcinoma cells c-Myc siRNA-mediated knockdown Cell lines [17]
ATM-ZEB1-Chk1 EMT-mediated breast cancer cell reprogramming ZEB1 shRNA-mediated knockdown Cell lines [21]
ATR-Chk1
ATM-Chk2
CD133+ glioblastoma cells Inhibition of Chk1 and Chk2 with
debromohymenialdisine (DBH)
Glioma xenografts, clinical
samples, cell lines
[16,18]
Chk2 ALDH+ prostate cancer cells ALDH inhibition with N,N-diethylaminobenzaldehyde
(DEAB) and galiellalactone, WNT pathway inhibition
with XAV939 and CTNNB1 siRNA-mediated
knockdown
Cell lines [22]
ATM-Chk2 CD24−/CD44+ breast cancer cells Inhibition of ATM with KU55933 Clinical samples, cell lines [15]
Chk1 CD133 + CD44+ prostate cancer cells Chk1 shRNA-mediated knockdown Cell lines [23]
PARP CD133+ glioblastoma cells PARP inhibition with olaparib Clinical samples [24]
Upregulated DNA repair genes (BRCA1, Exo1,
Rad51,Mre11a, Ku70, DNA PKC, Chk1, Fan1,
Msh2)
CD133+ lung cancer cells n/a Cell lines [14]
Protection from oxidative stress
by ROS scavenging
Overexpression of the genes controlling
glutathione biosynthesis (FoxO1, Gss, Gclm)
CD24medCD49fhigh murine mammary epithelial cells;
CD44+CD24−/low breast cancer cells; Thy+CD24+ mouse
murine mammary tumor cells isolated from MMTV-Wnt1
tumors
Decrease of glutathione with L-S,R-buthionine
sulfoximine (BSO) which inhibits glutamate-cysteine
ligase
Clinical samples, mouse tumors [29]
Overexpression of the genes controlling ROS
detoxiﬁcation (MT3, Prdx3, Apoe, Prdx4, Nme5,
Gpx1, Bnip3)
CD24−/low breast cancer cells Ectopic expression of CD24 Cell lines [28]
Activation of anti-apoptotic
pathways
WNT/β-catenin
PI3K/mTOR
CD44v6-mediated activation of WNT/β-catenin and
PI3K/mTOR signaling pathways
CD44v6 siRNA-mediated knockdown Cell lines [43]
WNT/β-catenin ALDH+ prostate cancer cells ALDH inhibition with N,N-diethylaminobenzaldehyde
(DEAB) and galiellalactone, WNT pathway inhibition
with XAV939 and CTNNB1 siRNA-mediated
knockdown
Cell lines [22]
WNT/β-catenin Enrichment of CSC by in vivo irradiation using orthotopic
glioma models
WNT pathway inhibition with XAV939 and CTNNB1
siRNA-mediated knockdown
Glioblastoma xenografts,
clinical samples, cell lines
[44]
Notch signaling CD133+ glioblastoma cells Inhibition of Notch signaling with γ-secretase
inhibitors DAPT or L685,458; Notch1 and Notch2
shRNA-mediated knockdown
Clinical samples [41]
Protection by
microenvironmental niche
Hypoxia dependent mechanisms ALDH+ prostate cancer cells Decrease of hypoxia in vivo by the inhibition of
tyrosine kinase receptors C-kit, VEGFR2 and PDGFRb by
sunitinib
Cell lines [35]
CD24−/CD44+ esophageal cancer cells n/a Cell lines [36]
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normoxic cells through less ROS generation and activation of the
hypoxia-inducible factor (HIF) signaling route [43–45]. The transcrip-
tion factors HIF-1α and HIF-2α are regulators of the gene transcription
at hypoxia response elements (HREs) that activate pro-survival devel-
opmental pathways such as Notch, wingless and INT-1 (WNT) and
Hedgehog [46–48]. Activation of these signaling pathways is essential
for CSC maintenance and associated with resistance to radiotherapy
and accelerated repopulation of CSCs during or after treatment [28,30,
49–51] (Table 1).
Another important factor is the epithelial–mesenchymal transition
(EMT) as a key process in regulation of tissue development, but also of in-
vasion and metastasis of tumors [52]. In pancreatic cancer, the presence
of pancreatic stellate cells has been shown to enhance radioresistance
and at the same time to promote EMT and to induce CSCmarker expres-
sion. Tumor take seemed to be accelerated andpotentially enhanced [53].
This link between EMT, CSC and radioresistance, although mechanisti-
cally not completely understood, is supported by preclinical in-vitro
data on prostate cancer cells [54] and lung cancer [55]. EMT may also
cause migration of tumor cells into blood vessels, where they are
detectable as circulating tumor cells (CTC) in many cancer patients.
The presence of CTC has been associated with an increased risk of
tumor recurrence and distant metastases. Features of EMT and CSCs
are often evident in CTC and have been shown to be a better predictor
of treatment outcome as compared to the sole number of CTC per vol-
ume of blood [56,57].Overall, an increasing body of evidence supports
a higher radioresistance of CSCs compared to the mass of tumor cells.
Underlying mechanisms are increasingly but by far not completely
unraveled. Open questions include why, if there is a major difference
in radioresponse between CSC and non-CSC, CSC-independent bio-
markers (see also below) can work at all as prognostic or predictive
markers for radiotherapy. Another interesting question is why for ra-
diotherapy alone the response of tumors in terms of growth delay, an
endpoint that depends on the mass of tumor cells, fairly correlates
with local control (TCD50), which depends on CSCs, whereas for com-
bined radiotherapy and non-CSC-active systemic treatments, strong ef-
fects on growth delay are observed with at the same time missing
effects on local tumor control [58]. Based on the knowledge that CSCs
are inactivated by irradiation, but just seem to require higher doses as
compared to non-CSC, it can only be speculatedwhether the correlation
between growth delay and local tumor control could be caused by an
existent correlation of CSC radiosensitivity and non-CSC radiosensitivity
that is not a 1:1 correlation but includes either a factor or a threshold
value.
3. Cancer stem cells as prognostic or predictive biomarkers in
patient tumors
Throughout its history, radiotherapy has taken into consideration
individual factors for treatment planning, like patient anatomy, tumor
localization, tumor stage or tumor mass. Recent data imply that speciﬁc
biological characteristics of the tumor are excellent biomarkers that can
serve as a basis for studies on further radiotherapy treatment individu-
alization (see below). Putative CSC markers have been evaluated for
many cancer types in preclinical and clinical studies. The following
section will discuss two tumor entities, i.e. head and neck squamous
cell carcinoma (HNSCC) and glioblastoma multiforme (GBM), that
have been evaluated frequently for the prognostic or predictive value
of CSC markers. For a review of other tumor entities see [59].
A seminal study on the impact of CSC marker expression and local
tumor control after radiotherapy has been published several years
ago: In patients with early laryngeal cancer treated by primary radio-
therapy with curative intention, gene expression proﬁling has been
performed retrospectively in the tumor material in order to identify
biomarkers that could predict tumor recurrence after radiotherapy. Pa-
tients with subsequent tumor recurrences were matched for otherrelevant parameters like T-stage, subsite, treatment, gender and patient
age with patients who did not develop tumor recurrences. The authors
generated whole genome gene expression data on the pre-therapeutic
biopsies from 52 patients followed by immunohistochemical analysis
in a validation cohort of 76 patients and demonstrated that CD44
mRNA and protein expression signiﬁcantly correlates with the risk of
tumor recurrence [60]. CD44 is a transmembrane glycoprotein receptor
interactingwith awide variety of the ECM ligands including hyaluronan
(HA), collagen, laminin, ﬁbronectin and osteopontin [61]. Although the
mechanisms of regulation of tumor radioresistance by CD44 are not
clear yet, a few in vitro studies demonstrated that CD44 can interplay
with epidermal growth factor receptor (EGFR) and activate c-Met,
focal adhesion kinase (FAK) and AKT signaling pathways and contrib-
utes to ROS defense by upregulation of reduced glutathione [62,63],
which in turn might lead to an increase of cell radioresistance [64–66].
Interestingly, in accompanying in-vitro experiments using different la-
ryngeal cancer cell lines, plating efﬁciency but not radiosensitivity cor-
related with CD44 expression [60]. Although plating efﬁciency is a
measure for clonogenicity of tumor cells, it does not always correlate
with tumorigenic properties. In addition, in vitro cell growth conditions
might not properly reﬂect a native tumor microenvironment including
oxygen tension, pH, growth factors and interaction with ECM proteins
which serve as CD44 ligands. Furthermore, the established cancer cell
lines cultured in vitro for decades possess multiple genetic alterations
and might very roughly resemble primary tumor cells. Therefore, the
data obtained with the common cell lines need to be interpreted with
caution [67]. Thus, although the data support that CD44 is a measure
for density of CSC rather than for their intrinsic radiosensitivity, the
question about putative intrinsic radioresistance of CD44 HNSCC cells
remains open and warrants further in vivo investigations [7]. Both
density and intrinsic radiosensitivity of CSC correlate with local tumor
control probability after radiotherapy [7] and it has been shown in ex-
perimental datasets in vivo that in tumors with the same histology
both parameters can be attributed to the intratumoral heterogeneity
of local tumor control probabilities after clinically relevant fractionated
irradiation [6].
In linewith these ﬁndings, recentmulticenter studies of the German
Cancer Consortium Radiation Oncology Group (DKTK-ROG) revealed a
signiﬁcant association of the expression of putative CSC markers with
locoregional tumor control after radiochemotherapy of HNSCC both
in the primary [Baumann, Linge, Lohaus et al., unpublished] as well
in the postoperative setting [Linge et al. under revision]. In the latter
study CD44, hepatocyte growth factor receptor (HGFR, also called
MET) and solute carrier family 3A2 (SLC3A2) expression in the surgical
specimen correlated with locoregional tumor recurrence, and in case of
MET and SLC3A2 also with distantmetastases in human papillomavirus
(HPV) negative HNSCC patients after surgery and postoperative radio-
chemotherapy [Linge et al., under revision]. This is of special interest
as postoperative radiochemotherapy is applied in order to inactivate
potentially remaining very lownumbers of tumor cells. In such datasets,
some patients may already have been cured by surgery alone, i.e. they
had no remaining tumor cells, which would be expected to weaken
prognostic or predictive values of all biomarkers that are thought to
measure sensitivity to postoperative treatments. The observation of a
signiﬁcant association between CSC markers and outcome of radiother-
apy after surgical removal of the tumor indicates that the number of CSC
remaining in the tumor bed or in the neck after surgery is high for tu-
mors with high CSC density compared to tumors with low CSC density.
Whether the mechanism is merely statistical, i.e. a higher proportion of
an otherwise similar number of tumor cells remaining after surgery is
CSC, or whether high CSC density tumors also show higher inﬁltrative
potential or metastatic escape via lymphatics is currently unknown
and warrants further investigation.
Another putative CSC marker for HNSCC is 26S proteasome activity,
a multicatalytic protease complex with regulatory functions in cell
cycle, DNA repair and cell survival [68]. As demonstrated in a clinical-
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activity correlated with a higher self-renewal capacity and a higher
tumorigenicity of the cell lines. In line with these experimental data,
patients who underwent primary radiochemotherapy for HNSCC had a
longer survival and higher locoregional tumor control rates if their tu-
mors showed a high 26S proteasome activity [69].
Another example with a substantial number of clinical datasets
is GBM. GBM belong to the tumor entities that are most resistant to
radio(chemo)therapy and to other forms of cancer treatment. There is
presently no chance of permanent tumor control. Radioresistance
of GBM can be partly explained by a comparably high intrinsic
radioresistance of clonogenic GBM cells [70] and thus likely also of
GBM-CSC. On the other hand, speciﬁcally more radio(chemo)therapy-
sensitive GBM, i.e. with hypermethylation of O-6-methylguanine-DNA
methyltransferase (MGMT) promotor, show higher frequencies of re-
currences outside the radiotherapy treatment volume compared
to MGMT non-methylated tumors [71], implying a high mobility of
tumor cells or multifocal tumor growth. MGMT removes temozolomide
(TMZ)-generated O6-methylguanine and thereby supports DNA repair.
Therefore, MGMT inactivation through promoter methylation is associ-
ated with a high sensitivity to TMZ treatment [72].
Glioma-initiating cells might originate from neural stem cells and
lineage restricted progenitor cells [73] and GBM stem cells are believed
to reside in the stem cell niche in the subventricular zones [74]. GBM
initial lesions with contact to the cortex and the subventricular zone
have been shown to recur frequently multifocally and outside of the
original treatment volume [75]. Although controversial [76], high radia-
tion doses to the subventricular zone may increase patient survival
[77–79]. This effect may be explained by a slow-down of proliferation
of precursor cells [80]. A putative CSC marker that has been intensively
investigated in a number of human cancers including glioma is the
membrane glycoprotein CD133 [81] and it has been suggested that
CD133 positive glioma CSCs are more resistant to drug treatment [82]
and to radiotherapy [23] compared to CD133 negative cells. However
clinical data on the prognostic value of CD133 expression in GBM re-
main controversial. The ﬁrst study providing evidence for a correlation
of higher stem cell content with worse outcome in GBM was a post-
hoc evaluation of tumor material collected within the phase II and
randomized phase III trials on adjuvant radiotherapy with or without
temozolomide [83,84]. Here, expression of HOX genes that play an im-
portant role in the developmental processes, status of MGMT methyla-
tion and high expression of the epidermal growth factor receptor
(EGFR) correlated with lower survival. The HOX gene set comprises
CD133 and was prognostic only for survival after postoperative radio-
chemotherapy but not after radiotherapy [85]. The association of HOX
gene expression with survival was validated in a second cohort of pa-
tients from the same trials, thus increasing the reliability of the dataset.
The data are in line with later publications showing a correlation of
higher CD133 protein expression [86,87] or gene expression [88] with
poor overall and progression free survival after postoperative radioche-
motherapy. In contrast to these data, in a prospective study on 61 con-
secutive patients receiving complete or partial surgical resection of
their GBM and adjuvant radiochemotherapy, in addition to patient re-
lated factors, MGMT hypermethylation and high CD133 mRNA expres-
sion correlated with better progression free and overall survival [89].
No signiﬁcant association of CD133 protein expression and survival
after radiochemotherapywas found in another study using immunohis-
tochemical techniques [90,91]. Interestingly, CD133 expression has
been shown to be higher in tumor recurrences compared to the initial
tumor. This increase could be explained by both CSC and non-cancer
neural stem cells and was associated with a longer survival [86]. Thus,
tumor recurrences have to be treated as a separate cohort for the eval-
uation of biomarkers. The contradictory data for the prognostic rele-
vance of CD133 in the primary treatment situation of GBM may in
parts be explained by inhomogeneous patient cohorts in some of the
datasets, by different location of the tumors with different likelihoodof out-off ﬁeld recurrence, by different techniques used for quantiﬁcation
of CD133 and by the setting of different threshold values for immunohis-
tochemical techniques to name only few. Overall, the data contradict
the use of CD133 as a sole marker for treatment individualization studies
in GBM.
4. Importance of further biomarkers for patient stratiﬁcation
The aim of a biology based patient stratiﬁcation for future treatment
individualization trials must be to identify patient groupswhose chance
of tumor cure after current standard treatment is approaching 100%
and/or patient groups with poor tumor control rates. Such patient
groups can then be brought into treatment de-escalation or treatment
intensiﬁcation trials, respectively. In contrast, for patients between
these extremes it is currently extremely difﬁcult to design a personal-
ized interventional strategywhich can be tested in clinical trialswithout
major risk to reduce their individual chance of uncomplicated tumor
control. For these patients, traditional clinical trials, accompanied by
translational studies into reﬁned biomarker panels, appear currently
as the best strategy. The deﬁnition of extremely good or very poor prog-
nosis group very likely requires the application of several biomarkers,
where CSC markers are only one of them.
For primary radio(chemo)therapy, tumor size is an established
biomarker that needs to be included as a relevant parameter into all
studies for patient stratiﬁcation for individualized radiotherapy. In a
re-evaluation of clinical data on different tumor entities from the litera-
ture, a sigmoid negative tumor volume–response curve could be
established. This curve correlatedwellwith the curve predicted from ra-
diobiological knowledge, but the predicted curve was overall steeper
than the curve adapted for the clinical data. The predicted curve as-
sumed that on average, the number of clonogens (here CSC) is increas-
ing linearly with tumor volume and that all other biological factors are
comparable between small and large tumors [4]. The strong correlation
of tumor volume and local tumor control after radiotherapy has been
supported by a number of clinical datasets [92,93] [Lohaus et al.,
DKTK, unpublished]. There is even evidence that the efﬁcacy of different
fractionation schedules of radiotherapy depends on the tumor volume
at the start of radiotherapy [94]. Along with inaccuracies of tumor
volume measurement and differences in treatment schedules, the
above mentioned more shallow decrease of the clinical curve is likely
to be explained by confounding factors that in addition to the number
of CSC explain tumor radiosensitivity, such as intrinsic radioresistance
or tumor micromilieu parameters like hypoxia [95]. The data show the
strong impact of tumor volume or CSC number on local tumor control
after radiotherapy, however, they also support the use of additional
biomarkers as a basis for patient stratiﬁcation, as demonstrated also
by a prospective evaluation on the impact of tumor volume in lung
cancer [96].
Especially for HNSCC, positivity of the tumor for high-risk subtypes
of the human papilloma virus (HPV) has been shown to lead to better
survival and locoregional tumor control after primary radio(chemo)-
therapy [97,98] [DKTK data in preparation]. The HPVs are small
double-stranded DNA viruses. Their genome encodes eight viral pro-
teins including the two pro-proliferative oncoproteins E6 and E7,
which lead to carcinogenesis by inhibition of the p53 and Rb tumor sup-
pressor pathways [99]. Underlying reasons for the higher radiosensitiv-
ity of HPV positive HNSCC may be an impaired DNA repair capacity in
HPV positive tumor cells [100] and/or higher immunogenic effects of
HPV positive tumors [101]. HPV positivity determined by p16 protein
expression or by HPV16 DNA positivity is already being widely used as
a stratiﬁcation parameter in prospective clinical trials in HNSCC.
Another important biological parameter is tumor hypoxia. Tumor
hypoxia increases tumor cell radioresistance [102]. Local tumor control
in experiments in vivo [103] and in patient tumors has been shown
to correlate with the extent of hypoxia or surrogate markers of
hypoxia [104–107]. Modiﬁcation of hypoxia during radiotherapy has a
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HNSCC, as shown in clinical trials [108]. The correlation of hypoxia with
outcome of radio(chemo)therapy may not only be a consequence of a
direct effect of hypoxia on tumor cell radioresistance, but also of a
more malignant phenotype and higher intrinsic radioresistance of hyp-
oxic tumors. This is supported by the fact that tumormodelswith higher
hypoxic volume are more radioresistant even if radiotherapy is per-
formed under artiﬁcially homogeneously anoxic conditions [6] and by
the fact that tumor hypoxia proﬁles determined withmRNA expression
arrays also correlatewith local tumor control in postoperative radioche-
motherapy, i.e. when the hypoxic primary tumor has been surgically
removed [Linge et al., under revision, see below]. Independent of the
underlying mechanisms, hypoxia appears to be a valuable biomarker
for prediction of radio(chemo)therapy outcome. Clinical studies are
today using mostly non-invasive techniques of hypoxia measurement,
e.g. by evaluation of gene panels in the surgical specimen or in the
tumor biopsy or, if the tumor is still in situ, imagingmodalities,most fre-
quently positron emission tomography (PET) with hypoxia-speciﬁc
tracers like 18F-misonidazole. These biomarkers have been demonstrated
to correlate with locoregional tumor control after primary radiochemo-
therapy in HNSCC [106,107,109–113]. Although there is an interaction
of hypoxia and CSC with CSC being able to sustain stem cell capabilities
under hypoxic more than under oxic conditions, both parameters cannot
be subsumed under the same biomarker [43].
The clinical value of multi-biomarker assays including CSC and hyp-
oxia markers has been demonstrated in the above mentioned multi-
center DKTK trial on biomarkers for locoregional tumor control after
post-operative radiochemotherapy. After postoperative radiochemo-
therapy in HNSCC patients, HPV16 DNA positivity led to locoregional
tumor control over 5 years was ~97% [114]. In the HPV16 DNA negative
group, locoregional tumor control over 5 years was ~80%, which
warrants additional biomarkers to further stratify this subgroup into ad-
ditional patients with favorable outcome and patients with very low
chance of locoregional tumor control. In additional analyses, hypoxia
gene panels and CSC markers have been evaluated. Indeed, patients
with HPV16 DNA negative tumors, high CSC marker expression (MET
or SLC3A2) and high hypoxia gene expression within the surgical spec-
imen showed much lower locoregional tumor control rates with ~65%.
On theother hand, lowCD44 expression inHPV16DNAnegative tumors
identiﬁed additional patients who belong to the advantageous group
with ~100% locoregional tumor control (Linge et al., under revision).
Further biomarker evaluations are underway in order to ﬁnd the most
promising parameters that can be used for later treatment individuali-
zation studies.a) Whole Patient population b) Stratification with
Fig. 1. Theoretical sketch of the potential value of multiple biomarker testing of a patient grou
strategies. a) The whole patient population has a certain dose response relationship, which,
b) Using one biomarker, e.g. a CSC marker, the whole population may be separated into tw
groups gets lower, thus the radiation dose – response relationships get steeper. c) The applic
still considerably different radiosensitivity. The steepness of the dose–response relationships
reduced. Such strategies lead to the fact that e.g. radiation dose escalation in the patient grou
the same approach applied to the whole patient population.Even though radiotherapy is a locoregional treatment, it is important
to also include biomarkerswith predictive potential for distantmetasta-
ses into panels that serve as a basis for treatment individualization. It is,
for example, not rational to increase the aggressiveness of locoregional
treatments at the risk of higher side effects, if for an individual patient
the risk of distant metastases is very high. Cancer stem cell markers
may serve as both, markers for locoregional control and for distant me-
tastases. Within the DKTK study, high MET and SLC3A2 expression was
also associated with 3–4 times higher rates of distant metastases. How-
ever, it has been shown preclinically that stem cell potential per se does
not necessarily increase metastatic potential [115], thus speciﬁc bio-
markers for metastatic CSC may help to increase the sensitivity of such
tests. In the above referenced article, microRNA-9 (miR-9) was shown
to distinguish between these two types of CSC. However, clinical data
on this topic are widely missing so far. Further reﬁnement of biomarker
evaluations will in future have the potential to select patient groups
which, due to their high risk of distant metastases, need additional
systemic treatment or which would even be candidates for omission
of intense local treatment.
Overall, the inclusion of established biomarkers together with
molecular or genetic testing for e.g. CSC marker proﬁles or other
markers of radioresistance will allow patient stratiﬁcation into sub-
groups with considerably different radioresistance that can in future
serve as a basis for treatment individualization. Higher stratiﬁcation
into more subgroups leads at the same time to lower heterogeneity
within the patient groups and thus to a steeper radiation dose–response
relationship (Fig. 1). As a consequence, treatment intensiﬁcation e.g. by
radiation dose escalation would be expected to lead to a comparably
higher increase in tumor control as compared to the same intensiﬁca-
tion applied to thewhole patient group or to lesser stratiﬁed subgroups.
5. Intratumoral heterogeneity and changes of biomarker proﬁles
during treatment
Tumor cell heterogeneity is attributed to the continued genetic and
epigenetic changes occurring within an individual clonogenic cell and
selected during somatic evolution, whichmight have a multidirectional
nature due to the spatial intratumoral diversity in the oxygen tension,
pH, nutrient supply, growth factor availability aswell as the cell content
within CSC niche. Intratumoral heterogeneity can lead to treatment
resistance due to awide variation of the response of different subpopula-
tions [116]. As demonstrated recently for example in renal cell carcinoma,
the majority of all somatic mutations detected by exome sequencing,
chromosome aberration analysis, and ploidy proﬁling on multiple 1 biomarker c) Stratification with more biomarkers 
p with the same tumor and, according to today's treatment standard the same treatment
due to the heterogeneity between the different individual tumors, is relatively shallow.
o distinct groups with different tumor radiosensitivity. The heterogeneity between the
ation of more biomarkers may allow the deﬁnition of more distinct patient groups with
gets again higher, because the heterogeneity between the patients in one group is again
ps with worse prognosis leads to higher increase in local tumor control as compared to
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was not present in all investigated tumor regions [117]. The study of
Kreso and co-workers demonstrated that not only genetic variety, but
also epigenetic changes might contribute to cancer growth and therapy
tolerance. This study employed DNA copy number alteration proﬁling,
deep sequencing and in vivo tracking of 150 single lineages derived
from 10 human colorectal cancers. These lineages were characterized
for their genetic pattern and repopulation dynamics after treatment
with oxaliplatin [118]. Using serial transplantation experiments, a dy-
namic regulation of CSC clones could be shown in these human colorectal
cancer cell lines [118], while genomic proﬁles of the primary human
tumor sample retained the same overall serially passaged xenografts,
the repopulation dynamics of distinct tumor subclones was heteroge-
neous with stability of some clones and transient detectability of other
clones. Distinct subclones increased over time, most likely due to initial
dormancy of the cells, others disappeared and re-appeared later again.
Along with these clonal changes, chemotherapy tolerance was different
between the different genetically identical subclones [118].
In addition to the genetic and epigenetic variety, tumor microenvi-
ronment also contributes to the functional diversity and evolution of
cancer cells, e.g. hypoxia and inﬂammationmight induce EMT and asso-
ciated epigenetic changes, and the presence of hypoxia was associated
with chromosomal instability [43,119,120]. Furthermore, different mi-
croenvironmental stimuli in vivo such as hypoxic conditions, anti-
cancer therapy or deﬁned genetic alterations can trigger epithelial to
mesenchymal transition and induce reprogramming of the differentiat-
ed tumor cells into induced CSC populations [121–123], thereby affect-
ing radioresistance. This may apply for heterogeneity within one tumor,
but also for changes under treatment. Therefore, resolving CSC hetero-
geneity during the course of treatmentmight be essential for the devel-
opment of biomarkers that reﬂect individual prognosis and predict
clinical outcome. Due to the palliative nature of chemotherapy alone
in solid tumors, this factor may be more relevant to chemotherapy
than to radiotherapy or surgery.
In preclinical experiments onprostate cancer cells, radiotherapy led to
upregulation of CSCmarkers and differentially regulated pathways (alde-
hyde dehydrogenase (ALDH) activity, OCT4, NANOG, BMI1, ATP-binding
cassette sub-family G member 2 (ABCG2), phosphatidylinositide 3-
kinases PI3K/AKT pathway activation, increased β-catenin and vimentin
expression as marker for EMT) [28] [Peitzsch et al., under revision]. At
the same time, a phenotypic switch during radiotherapy could be dem-
onstrated by the presence of the active histone methylation marks at
the promoter sequence of ALDH1A1 gene and, as a consequence, a
higher tumorigenicity and radioresistance of the prostate cancer cells
that underwent multiple irradiations. Interestingly and translationally
highly relevant, this histone methylation could be abrogated by treat-
ment with the methyltransferase inhibitor DZNep, leading at the same
time to an inhibition of tumorigenicity and radioresistance [Peitzsch
et al., under revision]. Similar variabilities of putative CSC markers dur-
ing radiotherapy have been shown for ALDH1A3 expression in HNSCC,
where an increase of the expression after irradiation by either induction
or selection correlates with in vivo tumor radiocurability [124]. Besides
a higher radioresistance of CSCs compared to non-CSC tumor cells, such
effects can be explained by a generation of new CSCs from previously
non-tumorigenic cells after irradiation [123,125], potentially as a conse-
quence of pro-inﬂammatory signaling within normal tissue cells of the
tumor microenvironment after irradiation [126] and/or due to hypoxic
microenvironmental conditions [127].
Variability under radiotherapy is also known for other biomarkers,
with hypoxia being one of the best evaluated markers. Mechanistically,
this is of special interest because interactions with CSC related bio-
markers may exist (see also above, CSC niches, Section “Radioresistance
determined by cancer stem cells”). In preclinical in-vivo experiments,
correlation of the hypoxic volume measured immunohistochemically
with pimonidazole was stronger when the biomarker was evaluated
after 2 weeks of the 6-week course of radiotherapy compared to a pre-treatment evaluation [128]. These datawere supported by a subsequent
clinical study showing the strongest correlation between hypoxia mea-
sured with 18F-misonidazole PET and locoregional tumor control when
hypoxia was evaluated after 2 weeks of radiochemotherapy [107]. A
validation study is currently under evaluation [Baumann Abstract
10LBA, ECCO 2015] and a prospective interventional trial is in prepara-
tion. Interestingly, not only the size, but also the spatial distribution of
hypoxic areas is heterogeneous during the course of radiochemothera-
py, a fact that needs to be considered when radiotherapy boost strate-
gies are evaluated for putatively radioresistant hypoxic areas [129].
Another example is the expression of the EGFR before and during radio-
therapy, which has been shown to be differentially regulated in differ-
ent individual tumor models of the same histology under the same
radiotherapy treatment schedule [130].
Overall, an increasing body of evidence supports the variability of
biomarkers during treatment together with consequences for the pre-
dictive value of the respectivemarker. These data warrant careful trans-
lational investigationswith repeated evaluations under treatment using
non-invasive or minimally invasive procedures, because the predictive
power of speciﬁc markers may in some cases also be determined by
its dynamics in the early treatment phase.6. Strategies to enhance efﬁcacy of radiotherapy by targeting cancer
stem cells
CSC targeting can be performed by either targeting of structures that
are overexpressed in CSC compared to non-CSC or by inhibition of path-
ways that are of higher importance in CSC compared to non-CSC. A
number of clinical trials are currently ongoing that use pharmacological
CSC targeting approaches in acute myeloid leukemia. So far little data
are available for solid tumors and speciﬁcally in the context of radio-
therapy. Approaches that are currently under preclinical investigation
are collected in Fig. 2. Few examples of promising experimental
targeting strategies with radiotherapy are discussed in the following:
In a translational study, the 3-hydroxy-3-methylglutaryl-coenzyme-
A-reductase (HMG CoA reductase) inhibitor simvastatin could be dem-
onstrated to radiosensitize mammosphere-initiating cells of different
inﬂammatory and triple negative breast cancer cell lines. In contrast, ra-
dioprotective effects of simvastatin were observed in two other non-
inﬂammatory breast cancer cell lines. In a retrospective clinical evalua-
tion of 519 patients with inﬂammatory breast cancer, the use of statins
was one of the factors that showed an independent association with
local recurrence free survival [131]. These data support the performance
of an early prospective clinical trial for this very-high-risk group of
breast cancer patients.
In pre-clinical experiments, an immunoconjugate of an anti-CD44v6
monoclonal antibody and the maytansinoid DM1, was applied during
fractionated irradiation in a human HNSCC tumor model. The simulta-
neous treatment led to a signiﬁcant improvement of permanent local
tumor control by a dose modifying factor of 1.9, which is substantial
compared to the majority of other experimental combined treatment
approaches [132]. Although the compound is not further pursued by
the manufacturer in the context of radiotherapy, these data strongly
support the evaluation of similar approaches using targets that have a
higher tumor speciﬁcity. In line with the before mentioned data, in a
clinical-preclinical trial in pancreatic cancer, patients with high tumor
expression of the standard isoform of CD44 correlatedwith signiﬁcantly
shorter overall survival compared to patients with lower expression. In
translational-preclinical experiments, anti-CD44 antibodies were ap-
plied alone orwith radiation. Although therewas no radiosensitizing ef-
fect of the drug in in-vitro colony formation assays, the drug alone
showed signiﬁcant cytotoxic effects on clonogenic tumor cells, reduced
in vitro cell viability and invasion as well as in vivo tumor growth in a
volume-based assay along with a down-regulation of stem cell self-
renewal genes Nanog, Sox-2, and Rex-1 [133].
Fig. 2. Cancer stem cells as targets for combined treatment. High-dose radiotherapy has the potential to cure solid tumors by inactivation of all cancer stem cells. Recurrences occur usually
from one or few remaining cancer stem cells. A combined treatment that speciﬁcally targets cancer stem cells or pathways that are of higher importance in cancer stem cells compared to
the mass of tumor cells, would be expected to increase local tumor control after combined treatment with radiotherapy. Some examples of possible interventions, that are already
preclinically tested, are given.
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bodies used as theragnostics, i.e. for diagnosis e.g. with positron emis-
sion tomography and, with another radionuclide, as a therapeutic
approach. Proof for this strategy has been shown with the radiolabelled
anti-EGFR antibody cetuximab that led to signiﬁcant improvement of
local tumor control when applied together with external beam radio-
therapy [134]. Such targeting approaches are in principal also possible
with other receptors or proteins that are higher expressed in the
tumor compared to surrounding normal tissues, including putative
CSC speciﬁc proteins [135].
Some early clinical trials that are ongoing or just ﬁnished evaluate
the applicability and efﬁcacy of e.g. NOTCHorHedgehog pathway inhib-
itors together with palliative radiotherapy. It is currently too early to
conclude on any of their results. Especially in the context of radiothera-
py, research strategies need to focus on combined treatments with
drugs that are as speciﬁc as possible to CSCwith no or onlyminor effects
in surrounding normal tissues in order to avoid an increase of radiogen-
ic toxicities in normal tissues. Another highly important issue is the bio-
availability of the drugs to the CSCs, which may be located in hypoxic
niches with little or no blood perfusion. This is especially critical if the
target of the drug is also expressed on non-CSCs that may be situated
closer to the vessel along the diffusion path and/or if the plasma half-
life of the drug is short. Such effects may hinder the inactivation of
CSCs by the drugs in vivo, even if there is a cytotoxic effect on CSCs
in vitro. The problem may be partly eluded by the development of
drugs with long plasma half-life and high speciﬁcity to CSCs (see
above) or by radiopharmaceutical approaches (see above) that use ra-
dionuclides with a range that covers also some surrounding cell layers,
however, therewith loosing speciﬁcity to CSCs.7. Conclusion
Overall, current preclinical and clinical ﬁndings suggest that CSC den-
sity and inherent radioresistance are indicative of tumor radiocurability,
underlining the great promise of CSC-related predictive tests for clinical
trials on radiotherapy individualization. Nevertheless, there are still
some pitfalls that have to be taken into consideration. In particular, an
increasing body of evidence supports the use of multiple-variable
approaches, where CSC markers may only be one part. Speciﬁcally,inclusion of known and long established biomarkers like tumor size
for primary radio(chemo)therapy or HPV infection status in HNSCC is
essential in order to deﬁne patient groupswith very different treatment
outcome as a basis for clinical trials on radiotherapy treatment individ-
ualization. This in turn leads to the necessity of large patient popula-
tions to be included into clinical trials, requiring multi-institutional
co-operation in order to recruit substantial patient numbers for highly
speciﬁed subgroups of tumors. In addition, speciﬁcally to CSC, a high
heterogeneity of different subclones (or reprogramming) within indi-
vidual tumors has been observed under treatment along with changes
of the functional behavior of the tumor, underlining the importance of
the selection of the optimal methods and timepoint(s) of biomarker
evaluation, but also providing a potential therapeutic target for com-
bined treatment approaches with irradiation.
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